Decision on Key Permit for Lithium Project Due Feb. 28
Source: Varun Arora 02/24/2025
Now, the outcome looks to be favorable given an overseeing Brazilian state agency recommended approval of the license, noted a Clarus Securities report.
Lithium Ionic Corp. (LTH:TSX.V; LTHCF:OTCQX; H3N:FSE) should know by month-end whether it will be granted the critical license needed to advance its Bandeira lithium project in Brazil, reported Varun Arora, Clarus Securities analyst, in a Feb. 19 research note. Receipt of this permit likely would lead to partial project funding and a rerating of the mining company.
“Management has continued to advance the key project development initiatives. Engineering and logistical preparations are well underway, which will allow Lithium Ionic to commence construction activities at Bandeira soon after the LAC approval,” Arora wrote, referring to the requisite Licença Ambiental Concomitante, an installation/construction license and an operating license in one.
Bandeira construction should take about 18 months, meaning first production could happen by late 2026, the analyst noted.
733% Return on Investment
A 733% return is implied in Clarus Securities’ price target on Lithium Ionic, Arora highlighted. Whereas the target is CA$8 per share, the lithium explorer is priced at about CA$0.96 per share.
Lithium Ionic remains a Speculative Buy.
Final Decision on Feb. 28
Arora reported that SEMAD, or the State Department of Environment and Sustainable Development, the regulatory body overseeing environmental licensing in Brazil’s Minas Gerais, recommended, in a technical report, Lithium Ionic be granted an LAC for Bandeira. The final decision, also noted in the report, is to be made on Feb. 28.
If the LAC is approved, the installation license, or LI, will be valid for four years. The operational license, or LO, will be valid for 10 years and may be renewed.
Warrants Higher Valuation
Investors should expect an upward rerating of Lithium Ionic if a LAC is granted, wrote Arora, given that LTH’s current valuation is much lower than that of two nearby lithium companies.
Lithium Ionic’s valuation is about CA$67 per ton of lithium carbonate equivalent, and Latin Resources’ implied valuation when it was acquired last year (when its project was at the preliminary economic assessment stage) was about CA$215 per ton. Were Latin Resources’ valuation multiple applied to Lithium Ionic, the resulting valuation would be about CA$250 million (CA$250M), or CA$2.50 per share on a fully diluted basis.
Similarly, if adjacent lithium producer Sigma Lithium Corp.’s (SGML:TSX.V; SGML:NASDAQ) valuation multiple were applied to Lithium Ionic, the resulting valuation would be about CA$1.2 billion (CA$1.2B), or CA$6.60 per share on a fully diluted basis.
Additionally, Arora wrote, Bandeira boasts “compelling economics,” specifically an after-tax net present value discounted at 8% of US$1.3B and an internal rate of return of 40%, according to the May 2024 feasibility study.
Bandeira is forecasted to produce, on average, 178,000 tons per year of spodumene concentrate grading 5.5% Li2O. Opex is estimated to be US$444 per ton, which Arora indicated is low.
Supports Funding Agreement
Receipt of a LAC also would bode well for Lithium Ionic receiving debt financing from the U.S. Import-Export Bank (EXIM) in an amount that would cover initial Bandeira capex, US$266M, purported Arora. EXIM and the lithium company have a nonbinding agreement in place pertaining to this.
“Finalizing the debt funding agreement with EXIM will result in lower dilution than currently modeled in our valuation for LTH, resulting in upside to our target price,” the analyst added.
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
Important Disclosures:
- Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
Disclosures for Clarus Securities Inc., Lithium Ionic Corp., February 19, 2025
Clarus Securities Equity Research Disclosures Within the last 24 months, Clarus Securities Inc. has managed or co-managed a public offering of securities of this company. Within the last 24 months, Clarus Securities Inc. has received compensation for investment banking services with respect to the securities of this company. General Disclosure The information and opinions in this report were prepared by Clarus Securities Inc. (“Clarus Securities”). Clarus Securities is a wholly-owned subsidiary of Clarus Securities Holdings Ltd. and is an affiliate of such. The reader should assume that Clarus Securities or its affiliate may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates and projections contained in this report are those of Clarus Securities as of the date of this report and are subject to change without notice. Clarus Securities endeavours to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Clarus Securities makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Clarus Securities or its affiliate that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security. No part of this report may be reproduced or re-distributed without the written consent of Clarus Securities. Conflicts of Interest The research analyst and/or associates who prepared this report are compensated based upon (among other factors) the overall profitability of Clarus Securities and its affiliate, which includes the overall profitability of investment banking and related services. In the normal course of its business, Clarus Securities or its affiliate may provide financial advisory and/or investment banking services for the issuers mentioned in this report in return for remuneration and might seek to become engaged for such services from any of such issuers in this report within the next three months. Clarus Securities or its affiliate may buy from or sell to customers the securities of issuers mentioned in this report on a principal basis. Clarus Securities, its affiliate, and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities discussed herein, or in related securities or in options, futures or other derivative instruments based thereon. Analyst’s Certification Each Clarus Securities research analyst whose name appears on the front page of this research report hereby certifies that (i) the recommendations and opinions expressed in the research report accurately reflect the research analyst’s personal views about the Company and securities that are the subject of this report and all other companies and securities mentioned in this report that are covered by such research analyst and (ii) no part of the research analyst’s compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed by such research analyst in this report. Equity Research Ratings Buy: Attractively valued and expected to appreciate significantly from the current price over the next 12-18 months. Speculative Buy: Expected to appreciate significantly from the current price over the next 12-18 months. Financial and/or operational risk is high in the analyst’s view. Accumulate: Attractively valued, but given the current market price, is expected to appreciate moderately over the next 12 -18 months. Hold: Fairly valued and expected to trade in line with the current price over the next 12-18 months. Sell: Overvalued and expected to decline from the current price over the next 12-18 months. Under review: Pending additional review and/or information. No rating presently assigned. Tender: Company subject to an acquisition bid: accept offer. A summary of our research ratings distribution can be found on our website. Dissemination of Research Clarus Securities’ Equity Research is available via our website and is currently distributed in electronic form to our complete distribution list at the same time. Please contact your Clarus institutional sales or trading representative or investment advisor for more information. Institutional clients may also receive our research via THOMSON and REUTERS. For additional disclosures, please visit our website http://www.clarussecurities.com. © Clarus Securities Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.
( Companies Mentioned: LTH:TSX.V; LTHCF:OTCQX; H3N:FSE, )
Source: https://www.streetwisereports.com/article/2025/02/24/decision-on-key-permit-for-lithium-project-due-feb-28.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
